No business profile yet.
Size TaiMed Biologics (4147.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $480M, the 446th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$60.60 on 18 Nov 2026.
Performance Over six months the shares gained 18.6%, against -14.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 18 in its peer set.
Growth Revenue grew 7.0% over the last twelve months (peer median -9.2%); the operating margin is -31.0% (peer median -11.6%).
Valuation It trades at 22.7× enterprise value to sales against a peer median of 7.5× (4th most expensive of 14).
Capital Return on invested capital runs 11.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$650M | NT$611M | NT$610M | NT$492M | NT$563M |
| Revenue growth | — | 0% | +24% | -13% | — |
| Gross profit | NT$252M | NT$203M | NT$155M | NT$168M | NT$154M |
| EBITDA | -NT$47.0M | -NT$41.7M | -NT$98.6M | -NT$11.5M | -NT$36.0M |
| Net income | -NT$164M | -NT$168M | -NT$202M | -NT$195M | -NT$269M |
| Free cash flow | -NT$48.7M | NT$168M | -NT$388M | -NT$31.8M | -NT$609M |
| Capital expenditure | NT$57.4M | NT$22.8M | NT$19.4M | NT$6.15M | NT$4.76M |
| Total debt | NT$471M | NT$493M | NT$523M | NT$751M | NT$766M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4147.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -11.1% | 4th highest of 21 |
| 6-month return | +18.6% | -14.1% | 4th highest of 18 |
| Distance from 52-week high | -19.6% | -46.1% | 3rd highest of 21 |
| Revenue growth (TTM) | +7.0% | -9.2% | 4th highest of 15 |
| Operating margin | -31.0% | -11.6% | 7th lowest of 15 |
| EV / Sales | 22.7× | 7.5× | 4th most expensive of 14 |
| ROIC minus cost of capital | -11.3 pp | -5.7 pp | 5th lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |